NVO

Novo-Nordisk A/S
D

NVO

108.020
USD
-0.05
(-0.05%)
Market Closed
Volume
152,542
EPS
23
Div Yield
1.34
P/E
36
Market Cap
479,787,720,439
News

Title: Novo/Nordisk A/S

Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.